Author: Erhardt Leif
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.14, Iss.6, 2005-06, pp. : 659-670
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Heart failure occurs in 2 – 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+ sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure.
Related content
Emerging therapies for heart failure
By Rudolph Amy E McMahon Ellen G
Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. :
Calcium Sensitising Agents in Heart Failure
Drugs & Aging, Vol. 12, Iss. 3, 1998-03 ,pp. :
Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry, Vol. 12, Iss. 2, 2016-03 ,pp. :